Evidence map›Paper›PMID 32060702›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2020

Oral adherence in adults with acute myeloid leukemia (AML): results of a mixed methods study.

Ashley Leak Bryant, Thomas W LeBlanc, Tara Albrecht, Ya-Ning Chan, Jaime Richardson, Matthew Foster, Malisa Dang, William Dudley, Susie Owenby, Debra Wujcik

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Designing a need-based program for relieving psychological distress of family caregivers of leukemia patients: a randomized controlled trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Trial
  2. Article
  3. Article
  4. Development, validation, and application of an LC-MS/MS method for the determination of the AXL/FLT3 inhibitor gilteritinib in mouse plasma.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2021
    Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ashley Leak BryantThe University of North Carolina at Chapel Hill, Carrington Hall, CB #7460, Chapel Hill, NC, 27599-7460, USA. ashley_bryant@unc.edu.
Thomas W LeBlancMedicine and Population Health, Duke University School of Medicine and the Duke Cancer Institute, Durham, NC, USA.
Tara AlbrechtDuke University School of Nursing, Durham, NC, USA.
Ya-Ning ChanThe University of North Carolina at Chapel Hill, Carrington Hall, CB #7460, Chapel Hill, NC, 27599-7460, USA.
Jaime RichardsonDivision of Hematology/Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, USA.
Matthew FosterDivision of Hematology/Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, USA.
Malisa DangDivision of Hematology, Oncology and Palliative Care, Virginia Commonwealth University, Richmond, VA, USA.
William DudleyPiedmont Research Strategies, Greensboro, NC, USA.
Susie OwenbyCarevive Systems, Inc., North Miami, FL, 33181, USA.
Debra WujcikCarevive Systems, Inc., North Miami, FL, 33181, USA.

Funding

Astellas, Inc None
6 · The paper itself

Abstract

introductionThe incidence of AML is increasing, in part due to an aging population. Since 2017, eight novel agents have been introduced, 6 of which are oral: midostaurin, enasidenib, ivosidenib, gilteritinib, glasdegib, and venetoclax. With an increase in oral medications (OMs), patients face associated side effects that accompany OMs, which often decreases adherence. We aimed to identify and summarize adherence to OMs in this population.

methodsOur mixed method design used focus groups (FG) and patient surveys. After IRB approval, 11 patients and 4 caregivers participated in 4 FGs. Themes from the FGs were used to develop a 37-item OMs adherence needs assessment. Participants were recruited and consented at three cancer centers to complete surveys (online, at the clinic, hospital, or from home).

resultsA total of 100 patients completed OMs survey. The number of pills to be taken was the most frequent and troublesome challenge. The most frequently reported interventions that would improve patient adherence were smaller pills, easier packaging, and scheduling assistance. Nearly 33% of patients indicated they skip OMs dose altogether when they forget to take it. Younger patients (< 65 years) were more accepting of taking oral compared with intravenous medications (p = .03).

conclusionThis study represents the first assessment of OMs adherence in adults with AML. Findings provide the basis for further exploration of interventions to enhance and increase adherence to OMs regimens.

Indexed as

Medication AdherenceAdministration, OralAgedAge FactorsAntineoplastic AgentsCaregiversHumansLeukemia, Myeloid, AcuteMaleMiddle AgedAntineoplastic AgentsAcute myeloid leukemiaBarriersMedication assessmentOral adherenceSide effectsSymptoms

Identifiers

PMID32060702

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.